iCAD (NASDAQ:ICAD) Upgraded to Buy by ValuEngine

ValuEngine upgraded shares of iCAD (NASDAQ:ICAD) from a hold rating to a buy rating in a report released on Thursday, ValuEngine reports.

Shares of iCAD stock traded up $0.03 on Thursday, reaching $7.00. The stock had a trading volume of 3,295 shares, compared to its average volume of 63,672. The business’s 50-day moving average price is $6.31 and its two-hundred day moving average price is $5.76. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.85 and a current ratio of 2.00. iCAD has a fifty-two week low of $2.42 and a fifty-two week high of $7.45. The stock has a market cap of $125.97 million, a P/E ratio of -18.13 and a beta of 1.15.

iCAD (NASDAQ:ICAD) last issued its quarterly earnings data on Thursday, August 1st. The technology company reported ($0.09) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.01. iCAD had a negative net margin of 43.88% and a negative return on equity of 61.62%. The business had revenue of $7.33 million during the quarter, compared to analysts’ expectations of $6.69 million. As a group, equities analysts forecast that iCAD will post -0.58 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the company. Spark Investment Management LLC acquired a new stake in shares of iCAD in the first quarter worth $185,000. Acadian Asset Management LLC lifted its stake in shares of iCAD by 118.5% in the second quarter. Acadian Asset Management LLC now owns 92,180 shares of the technology company’s stock worth $588,000 after buying an additional 50,001 shares during the last quarter. EAM Global Investors LLC acquired a new stake in shares of iCAD in the first quarter worth $984,000. Deutsche Bank AG raised its stake in iCAD by 33.5% during the 4th quarter. Deutsche Bank AG now owns 35,923 shares of the technology company’s stock valued at $132,000 after purchasing an additional 9,023 shares during the last quarter. Finally, Granite Investment Partners LLC acquired a new position in iCAD during the 2nd quarter valued at $451,000. Institutional investors and hedge funds own 24.70% of the company’s stock.

About iCAD

iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.

See Also: What is a stock portfolio tracker?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit